Skip to main content
Guerbet logo

Guerbet — Investor Relations & Filings

Ticker · GBT ISIN · FR0000032526 LEI · 969500WV1U1WQ059L135 PA Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2009-03-11 Earnings Release
Country FR France
Listing PA GBT

About Guerbet

https://www.guerbet.com

Guerbet is a global specialist in medical imaging, offering a comprehensive range of solutions and services for diagnostic and interventional procedures. The company develops and manufactures contrast media, medical devices such as injectors, and related software for X-ray, Magnetic Resonance Imaging (MRI), and Interventional Imaging. With a history of innovation dating back to 1926, Guerbet focuses on providing healthcare professionals with tools to enhance diagnostic accuracy and improve patient care. Its portfolio is designed to support a wide array of clinical applications, from initial diagnosis to treatment monitoring.

Recent filings

Filing Released Lang Actions
Des résultats 2008 en progression et porteurs d'avenir
Earnings Release Classification · 98% confidence The document provides a summary of the company's financial performance for the year 2008, including key metrics like revenue, operating income, net income, and R&D expenses, presented in a tabular format with comparative figures from 2007. It also discusses business highlights (Dotarem success), R&D efforts, investment plans, and concludes with a proposal for the dividend to be presented at the upcoming General Assembly. This structure—a concise summary of annual financial results and key operational achievements—is characteristic of an Earnings Release (ER), which typically precedes the full Annual Report (10-K) or serves as the initial public announcement of the period's results. Since it focuses on 'résultats 2008' and provides key figures but is not the comprehensive 10-K, 'ER' is the most appropriate classification. It is not a full transcript (CT), a formal audit report (AR), or a proxy statement (PSI). FY 2008
2009-03-11 French
Improved results in 2008 highlight positive trends for future
Earnings Release Classification · 97% confidence The document provides consolidated financial highlights for the year 2008, including key metrics like Net sales, Operating income, and Net income, along with commentary on R&D, capital spending, and future outlook. It explicitly mentions the Executive Board will ask the General Meeting to approve a dividend. This structure—a summary of annual performance with forward-looking statements and key financial tables—is characteristic of an Earnings Release (ER) or potentially a section of an Annual Report (10-K). However, given the brevity (4651 characters) and the focus on summarizing the *results* rather than providing the full statutory disclosures of a 10-K, it strongly aligns with an Earnings Release (ER). It is not a full Annual Report (10-K), an Audit Report (AR), or a Dividend Notice (DIV), as it contains much more operational and strategic context than just the dividend amount. It is a release of period results. FY 2008
2009-03-11 English
Guerbet 2008 net sales
Earnings Release Classification · 98% confidence The document is titled 'PRESS RELEASE' and provides consolidated group sales figures for the full year 2008 compared to 2007, broken down by quarter and region. It discusses product performance (Dotarem, Xenetix) and mentions capital expenditure and debt management for the fiscal year 2008. This content strongly indicates the release of preliminary or summary financial results for a period. The key differentiator is the final sentence: 'A complete presentation of Group results for fiscal 2008 with comments will be published on 11 March 2009.' Since this document is the initial announcement of the 2008 results (highlights only) and precedes the full presentation, it fits the definition of an Earnings Release (ER). It is too detailed for a simple RPA, but it is not the comprehensive annual report (10-K) or the detailed management discussion (MDA) that would follow. FY 2008
2009-02-11 English
Chiffre d'Affaires du quatrième trimestre 2008
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE" and focuses on the "Chiffre d'affaires 2008" (2008 Revenue). It presents consolidated revenue figures for the full year 2008, broken down by quarter and geography, and discusses key product performance (Dotarem, Xenetix). This content structure—a press release summarizing key financial metrics for a period—is characteristic of an Earnings Release (ER). The document explicitly states that the full results and related commentary will be made public on March 11, 2009, confirming this document is the initial, high-level announcement, not the comprehensive report (like a 10-K or IR). FY 2008
2009-02-11 French
Feu vert au financement du programme Iseult
Regulatory Filings Classification · 97% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a significant event: the European Commission's approval of funding for the Iseult program, led by Guerbet, related to future medical imaging (MRI). This is a general corporate announcement regarding a major strategic development (government funding/partnership for R&D) rather than a mandatory regulatory filing like a 10-K, an earnings release (ER), or a specific shareholder vote result (DVA). Since it details a major corporate event, partnership, and funding approval, it fits best under a general announcement category. Given the options, it is not a standard financial report, management change, or insider trade. It is a significant corporate communication. While 'RNS' (Regulatory Filings/Miscellaneous) is a fallback, this specific type of announcement about major R&D funding and strategic partnership is often classified as a general corporate update. However, since it is a press release announcing a major strategic/financing development (government aid approval), and it doesn't fit perfectly into the highly specific financial categories (like 10-K, ER, DIV), it leans towards a general announcement. Given the context of major financing/R&D news, 'CAP' (Capital/Financing Update) might seem relevant due to the 54 million euro aid, but the core focus is the R&D program approval itself. Since it is a press release announcing a major corporate event that doesn't fit the specific financial reporting codes, 'RNS' (Regulatory Filings/Miscellaneous) is the most appropriate general category for non-standard, material corporate news releases.
2008-12-11 French
The European Commission has approved funding for the Iseult programme
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that the European Commission has approved funding for the Iseult programme, coordinated by Guerbet. It details the funding amounts, partners (Siemens, CEA, etc.), and the purpose of the research (medical imaging, Alzheimer's diagnosis). This type of announcement, which is not a formal regulatory filing (like 10-K or IR), nor a standard earnings release (ER), nor a management discussion (MDA), but rather a significant corporate development announcement regarding financing/grants for a major project, fits best under 'Capital/Financing Update' (CAP) as it directly concerns securing substantial funding (€54 million grant). It is too specific for the general 'RNS' fallback, and while it involves research, it's primarily a financial/strategic announcement about securing the grant.
2008-12-11 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.